Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) on December 14, 2020. The registrant is a Delaware corporation headquartered in South San Francisco, California. The filing primarily serves to disclose non-public information regarding the company's research and development activities under Regulation FD.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on regulatory disclosure of corporate presentations rather than financial performance reporting.
Material Changes
There are no material changes to financial position or operations reported in this document. The significant event reported is the delivery of a presentation on the company's complement programs and its first subcutaneously-dosed systemic complement development candidate during a Research & Development Call.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: The company furnished a "Complement Presentation" and an updated "Corporate Presentation" to the public.
- Content: The presentations covered the company's complement programs and a specific development candidate.
- Legal Status: The information provided in this Item 7.01 and the attached exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Complement Presentation) and Exhibit 99.2 (Corporate Presentation) for specific clinical data or strategic updates.
- Confirm the company's current cash runway and burn rate by reviewing the most recent 10-Q or 10-K, as this 8-K contains no financial figures.
- Monitor upcoming clinical trial milestones for the subcutaneously-dosed systemic complement candidate mentioned in the presentation.